肝脏疾病中表达TREM2的巨噬细胞。
TREM2-expressing macrophages in liver diseases.
作者信息
Wang Xiaochen, Qiu Zhiyu, Zhong Zhenyu, Liang Shuang
机构信息
Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510030, China; Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
出版信息
Trends Endocrinol Metab. 2025 May 13. doi: 10.1016/j.tem.2025.04.009.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of the global population and spans a spectrum of liver abnormalities, including simple steatosis, inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Recent studies have identified triggering receptors expressed on myeloid cells 2 (TREM2)-expressing macrophages as key regulators of MASLD progression. TREM2 plays a pivotal role in regulating macrophage-mediated processes such as efferocytosis, inflammatory control, and fibrosis resolution. Additionally, soluble TREM2 (sTREM2) was proposed as a noninvasive biomarker for diagnosing and monitoring MASLD progression. However, the molecular mechanisms through which TREM2 influences MASLD pathogenesis remain incompletely understood. This review summarizes the current understanding of TREM2-expressing macrophages in MASLD, with the goal of illuminating future research and guiding the development of innovative therapeutic strategies targeting TREM2 signaling pathways.
代谢功能障碍相关脂肪性肝病（MASLD）影响着全球超过30%的人口，涵盖一系列肝脏异常情况，包括单纯性脂肪变性、炎症、纤维化、肝硬化和肝细胞癌（HCC）。最近的研究已确定表达髓系细胞触发受体2（TREM2）的巨噬细胞是MASLD进展的关键调节因子。TREM2在调节巨噬细胞介导的过程中发挥关键作用，如吞噬作用、炎症控制和纤维化消退。此外，可溶性TREM2（sTREM2）被提议作为诊断和监测MASLD进展的非侵入性生物标志物。然而，TREM2影响MASLD发病机制的分子机制仍未完全阐明。本综述总结了目前对MASLD中表达TREM2的巨噬细胞的认识，旨在为未来的研究提供思路，并指导针对TREM2信号通路的创新治疗策略的开发。
Zotero 插件